Hyaluronidase (Human Recombinant)
- Atc Codes:B06AA03
- CAS Codes:757971-58-7
- PHARMGKB ID:757971-58-7
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Dosage
- Special Considerations
Brand Names
Europe
Austria: Hylase Dessau; Czech Republic: Hylase Dessau; Germany: Hylase Dessau; Greece: Hyalase; Ireland: Hyalase; Malta: Hyalase; Netherlands: Hyason; UK: Hyalase.
North America
USA: Amphadase, Hydase, Hylenex, Vitrase.
Latin America
Argentina: Unidasa; Brazil: Hyalozima.
Drug combinations
Hyaluronidase and Betamethasone
Hyaluronidase and Lidocaine
Hyaluronidase, Lidocaine, and Neomycin
Other Hyaluronidase combinations: Aesculus hippocastanum; Aluminium oxydatum; Ambra grisea; Ammonium bituminosulfonicum; Anamirta cocculus; Apis mellifera; Araneus diadematus; Barium carbonicum; Barium chloratum; Berberis vulgaris; Bryonia spp.; Cinchona pubescens; Conium maculatum; Ferrum metallicum; Hawthorn; Lead acetate; Lophophora williamsii; Lycopodium clavatum; Nicotiana tabacum; Phytolacca americana; Plumbum aceticum; Sanguinaria canadensis; Solanum dulcamara; Sulfur; Toxicodendron quercifolium; Urtica urens; Viscum album; Zincum metallicum
Chemistry
Hyaluronidase (Human Recombinant): C~2327~H~3553~N~589~O~667~S~20~. Mw: approx. 51.11. (1) 36-482-Hyaluronoglucosaminidase PH20 (human); (2) Hyaluronidase 1 (human sperm surface protein PH-20)-(1-447) peptide. CAS-757971-58-7 (2005).
Pharmacologic Category
Other Hematological Agents. Homeopathic Products. Enzyme. (ATC-Code: B06AA03).
Mechanism of action
Modifies permeability of connective tissue through hydrolysis of hyaluronic acid, one of the chief components of tissue cement which offers resistance to diffusion of liquids through tissues. Hyaluronidase increases both distribution and absorption of locally-injected substances.
Therapeutic use
Increases dispersion and absorption of other drugs. Increases rate of absorption of parenteral fluids given by hypodermoclysis. Adjunct in subcutaneous urography for improving resorption of radiopaque agents.
Pregnancy and lactiation implications
Use only if clearly needed in pregnancy. Use with caution in lactation.
Unlabeled use
Management of drug extravasations.
Contraindications
Hypersensitivity to hyaluronidase or any component of the formulation.
Warnings and precautions
Should not be administered intravenously. Avoid injection in or around infected or inflamed areas (may spread localized infection). Should not be applied directly to cornea. Should be discontinued if sensitization occurs. Should not be used for extravasation management of dopamine or α-agonists or to reduce swelling of bites or stings.